Biosante Pharmaceuticals (BPAX)
|
1.35
+0.02 (+1.50%)
|
|
|
|
BPAX additional information
Market Data powered by QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Filings and Fundamentals by Morningstar, Insiders by Vickers (USA) and SEDI(CDN), analyst ratings by Zacks.
BPAX Profile
•
Exchange
NASDAQ
•
Held by these Mutual Funds
iShares Russell 2000 Growth Index
Vanguard Extended Market Idx
DFA US Micro Cap I
iShares Russell Microcap Index
Fidelity Spartan Extended Mkt Index Inv
BlackRock Global Allocation B
Bridgeway Ultra-Small Company Market
VALIC Company I Small Cap
DFA U.S. Small Cap Value II
DFA US Small Cap I
Vanguard Extended Market Idx
DFA US Micro Cap I
iShares Russell Microcap Index
Fidelity Spartan Extended Mkt Index Inv
BlackRock Global Allocation B
Bridgeway Ultra-Small Company Market
VALIC Company I Small Cap
DFA U.S. Small Cap Value II
DFA US Small Cap I
•
Competitors
•
Executives
Mr. Stephen M. Simes
Vice Chairman
Chief Exec. Officer and Pres
Mr. Phillip B. Donenberg CPA
Chief Financial Officer
Principal Accounting Officer Sr. VP of Fin. and Sec.
Dr. Michael C. Snabes M.D. .D.
63
Sr. VP of Medical Affairs
Dr. Jeffrey W. Winkelman Ph.D. D.
VP of Intellectual Property and Contracts
Ms. Joanne Zborowski r>VP of Clinical Devel.
Vice Chairman
Chief Exec. Officer and Pres
Mr. Phillip B. Donenberg CPA
Chief Financial Officer
Principal Accounting Officer Sr. VP of Fin. and Sec.
Dr. Michael C. Snabes M.D. .D.
63
Sr. VP of Medical Affairs
Dr. Jeffrey W. Winkelman Ph.D. D.
VP of Intellectual Property and Contracts
Ms. Joanne Zborowski r>VP of Clinical Devel.
•
Employee Count
54
Special Offers
Competitors
BPAX earnings
Date
Actual
Expected
Prev Yr Qtr
11/8/2012
-0.27
-0.30
-0.72
8/1/2012
-0.36
-0.41
-0.96
5/8/2012
-0.09
-0.06
-0.20
